Regeneron Pharmaceuticals, Inc.
Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments
Last updated:
Abstract:
The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
Status:
Grant
Type:
Utility
Filling date:
18 Aug 2020
Issue date:
13 Apr 2021